<i>In Vitro</i>
            Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

Lob, Sibylle; Hackel, Meredith; Kazmierczak, Krystyna M.; Young, Katherine; Motyl, Mary; Karlowsky, James A.; Sahm, Daniel F.

doi:10.1128/aac.02209-16

Cited by 119 publications

(88 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results showed that both Imipenem and Amikacin are effective antibiotics against all gram negative bacilli isolates. The latter is in concomitant with a recent work where both Imipenem and Amikacin were well effective against gram negative bacilli [28]. The E. coli isolates in our specimens showed various degrees of resistance to Ciprofloxacin, Co-trimoxazole, Tetracycline, Gentamicin which is in agreement with a similar study where E. coli resisted to these antibiotics with a slight differences [29].…”

Section: Discussionsupporting

confidence: 81%

Impact of Some Antibiotics on Bacteria Isolated from Appendices in Kirkuk Province, Iraq

Bazzaz¹,

Lor²,

Mahdi³

2018

ABB

View full text Add to dashboard Cite

A bacteriological study of 50 appendectomy cases for patients diagnosed by physicians to be appendicitis, within Kirkuk province was carried out to isolate the habitat bacteria of appendix and to assess the impact of some antibiotics on isolated bacterial species from the appendices. The age of patients ranged between 3 -45 year old (21 male and 29 female). The culture results showed 94% single isolate with 2% negative growth and 4% mixed growth were obtained. The gram positive bacteria isolate formed (11.77%) less than gram negative (88.23%). The total isolates represented 51 included Escherichia coli 34 (66.66%), followed by Enterococcus faecalis 3 (5.89%), Klebsiella pneumonia 3 (5.89%), Citrobacter youngae 2 (3.92%), Raultella terrigena 2 (3.92%), Pseudomonas aeruginosa 2 (3.92%), Enterrobacter cloacae 1 (1.96%), Serratia fonticola 1 (1.96%), Entercoccus faecium 1 (1.92%), Staphylococcus epidermides 1 (1.96%) and Staphylococcus xylosus 1 (1.96%). The Staphylococcus xylosus was the first time to be isolated in Kirkuk city while both of Raultella terrigena and Citrobacter youngae were isolated for the first time in appendix samples. Only 16 various antibiotics were tested against Enterobacteriaceae and Pseudomonas aeruginosa while 12 and 7 against Staphylococcus sp. and Enterococcus sp., respectively. The Imipenem and Amikacin were found to be most effective antibiotics against all Enterobacteriaceae isolates and Pseudomonas aeruginosa while Ampicillin, Piperacillin, Ceftazidime, Augmentin, and Cephalothin were ineffective against all isolated bacteria. The Penicillin and Vancomycin were effective against gram positive bacteria.

show abstract

Section: Discussionsupporting

confidence: 81%

Impact of Some Antibiotics on Bacteria Isolated from Appendices in Kirkuk Province, Iraq

Bazzaz¹,

Lor²,

Mahdi³

2018

ABB

View full text Add to dashboard Cite

show abstract

“…IMI‐REL has been evaluated against Enterobacteriaceae in several studies (Table 1). Overall, IMI‐REL demonstrates excellent in vitro activity, with susceptibility rates above 95% for Klebsiella pneumoniae , Escherichia coli , Citrobacter spp . , and Enterobacter spp .…”

Section: Microbiology and Spectrum Of Activitymentioning

confidence: 98%

“…Activity of IMI‐REL against Pseudomonas aeruginosa has been evaluated in several in vitro studies (Table 1). In general, 94% of P. aeruginosa demonstrated susceptibility to IMI‐REL. However, susceptibility rates were lower among P. aeruginosa with known resistance to imipenem.…”

Section: Microbiology and Spectrum Of Activitymentioning

confidence: 99%

See 1 more Smart Citation

Imipenem‐Cilastatin‐Relebactam: A Novel β‐Lactam–β‐Lactamase Inhibitor Combination for the Treatment of Multidrug‐Resistant Gram‐Negative Infections

2020

View full text Add to dashboard Cite

Imipenem‐cilastatin‐relebactam (IMI‐REL) is a novel β‐lactam–β‐lactamase inhibitor combination recently approved for the treatment of complicated urinary tract infections (cUTIs) and complicated intraabdominal infections (cIAIs). Relebactam is a β‐lactamase inhibitor with the ability to inhibit a broad spectrum of β‐lactamases such as class A and class C β‐lactamases, including carbapenemases. The addition of relebactam to imipenem restores imipenem activity against several imipenem‐resistant bacteria, including Enterobacteriaceae and Pseudomonas aeruginosa. Clinical data demonstrate that IMI‐REL is well tolerated and effective in the treatment of cUTIs and cIAIs due to imipenem‐resistant bacteria. In a phase III trial comparing IMI‐REL with imipenem plus colistin, favorable clinical response was achieved in 71% and 70% of patients, respectively. Available clinical and pharmacokinetic data support the approved dosage of a 30‐minute infusion of imipenem 500 mg–cilastatin 500 mg–relebactam 250 mg every 6 hours, along with dosage adjustments based on renal function. In this review, we describe the chemistry, mechanism of action, spectrum of activity, pharmacokinetics and pharmacodynamics, and clinical efficacy, and safety and tolerability of this new agent. The approval of IMI‐REL represents another important step in the ongoing fight against multidrug‐resistant gram‐negative pathogens.

show abstract

“…The spread of carbapenemase-producing Enterobacteriaceae (CPE) represents a serious threat for public health and requires their rapid identification to implement proper infection control measures to prevent further spread in hospitals and initiate proper treatments. Although very few novel antibiotics are, or will be, available for the treatment of CPE, the most promising therapies involve combinations of a broad-spectrum ␤-lactam and novel ␤-lactamase inhibitors (e.g., ceftazidime-avibactam, imipenem-relebactam) active on class A carbapenemases and on class D (for avibactam only) but not on MBLs (6,7). During the last 3 years, several methods have been developed for the detection of CPE, including (i) tests able to detect carbapenem-hydrolyzing activity (Carba NP test and derivatives [8][9][10], matrix-assisted laser desorption ionization-time of flight [MALDI-TOF] protocols [11,12], Bogaerts-Yunus-Glupczynski [BYG] test [13], carbapenem inactivation method [CIM] test [14,15], and ␤ Carba [16]), (ii) immuno-chromatographic tests for the rapid detection of KPC, OXA-48-type, and NDM carbapenemases (17)(18)(19), (iii) combination disk diffusion assays (20), and (iv) molecular-based techniques that aim to detect the most widespread carbapenemase-encoding genes (21)(22)(23).…”

mentioning

confidence: 99%

Comparison of Two Phenotypic Algorithms To Detect Carbapenemase-Producing Enterobacteriaceae

Dortet

Bernabeu

Gonzalez

et al. 2017

Antimicrob Agents Chemother

View full text Add to dashboard Cite

A novel algorithm designed for the screening of carbapenemase-producing Enterobacteriaceae (CPE), based on faropenem and temocillin disks, was compared to that of the Committee of the Antibiogram of the French Society of Microbiology (CA-SFM), which is based on ticarcillin-clavulanate, imipenem, and temocillin disks. The two algorithms presented comparable negative predictive values (98.6% versus 97.5%) for CPE screening among carbapenem-nonsusceptible Enterobacteriaceae. However, since 46.2% (n ϭ 49) of the CPE were correctly identified as OXA-48-like producers by the faropenem/temocillin-based algorithm, it significantly decreased the number of complementary tests needed (42.2% versus 62.6% with the CA-SFM algorithm).KEYWORDS OXA-48, KPC, NDM, VIM, IMP disk diffusion susceptibility testing, bacterial susceptibility testing, carbapenemase, disk diffusion C arbapenem resistance caused by carbapenemase production has been increasingly reported worldwide in Enterobacteriaceae (1, 2). In most of the cases, these carbapenemases belong to Ambler class A (mostly KPC and GES types) (3), Ambler class B or metallo-␤-lactamases (MBLs) of VIM, IMP (1, 2), and NDM types (4), or carbapenemhydrolyzing Ambler class D ␤-lactamases (CHDLs) (mostly OXA-48-like) (5). The spread of carbapenemase-producing Enterobacteriaceae (CPE) represents a serious threat for public health and requires their rapid identification to implement proper infection control measures to prevent further spread in hospitals and initiate proper treatments. Although very few novel antibiotics are, or will be, available for the treatment of CPE, the most promising therapies involve combinations of a broad-spectrum ␤-lactam and novel ␤-lactamase inhibitors (e.g., ceftazidime-avibactam, imipenem-relebactam) active on class A carbapenemases and on class D (for avibactam only) but not on MBLs (6, 7). During the last 3 years, several methods have been developed for the detection of CPE, including (i) tests able to detect carbapenem-hydrolyzing activity (Carba NP test and derivatives [8][9][10] , (iii) combination disk diffusion assays (20), and (iv) molecular-based techniques that aim to detect the most widespread carbapenemase-encoding genes (21-23).The ability to infer from routine antibiogram the presence of a carbapenemase is often complicated and requires complementary tests, leading to additional delay and cost for clinical laboratories. Accordingly, it is of importance to develop solutions (e.g., algorithms) with high sensitivities and negative predictive values (NPVs) to discriminate

show abstract

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)

Cited by 119 publications

References 22 publications

Impact of Some Antibiotics on Bacteria Isolated from Appendices in Kirkuk Province, Iraq

Impact of Some Antibiotics on Bacteria Isolated from Appendices in Kirkuk Province, Iraq

Imipenem‐Cilastatin‐Relebactam: A Novel β‐Lactam–β‐Lactamase Inhibitor Combination for the Treatment of Multidrug‐Resistant Gram‐Negative Infections

Comparison of Two Phenotypic Algorithms To Detect Carbapenemase-Producing Enterobacteriaceae

Contact Info

Product

Resources

About